Source comparison
BPC-157 for Muscle Tear: Research vs Clinical Comparison
Dosing Range 200–400 mcg/kg in rats (10–20 mcg absolute dose for 250g rat) 250–500 mcg total dose twice daily in 70kg human via body surface area scaling Dosing remains theoretical. No controlled human trials exist, all protocols are extrapolations from animal
This comparison does not assign a generated winner or score.
- Dosing Range
- 200–400 mcg/kg in rats (10–20 mcg absolute dose for 250g rat)
- 250–500 mcg total dose twice daily in 70kg human via body surface area scaling
- Dosing remains theoretical. No controlled human trials exist, all protocols are extrapolations from animal data
- Administration Route
- Subcutaneous injection near injury site or intraperitoneal (systemic)
- Subcutaneous injection 2–3 cm proximal/distal to injury; avoid intramuscular at tear site
- Localized subcutaneous showed superior outcomes vs systemic in comparative rodent studies
- Treatment Duration
- 14–28 days in acute injury models; up to 8 weeks in chronic tendinopathy studies
- 4–6 weeks covering proliferative phase through early remodeling
- Stopping at 2 weeks misses the collagen cross-linking window (weeks 3–5) when tensile strength rebuilds
- Healing Acceleration
- 40–70% faster return to baseline tensile strength in transection models
- Unknown. No human RCTs quantifying recovery time reduction exist
- Animal efficacy doesn't guarantee equivalent human response. Species differences in growth factor receptor density may alter effect size
- Side Effect Profile
- No adverse events reported across multiple rodent studies at therapeutic doses
- Unknown. Human safety data limited to anecdotal reports and case series without systematic monitoring
- Lack of toxicity in animals is reassuring but insufficient to confirm human safety across diverse populations